Richard Jones, MD
Rheumatology · Northport, ALNPI 1174507800
Payments from drug & device makers
Across 1,406 payments — averaging $206.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$113K
- Mallinckrodt Hospital Products Inc.$39K
- Aurinia Pharma U.S., Inc.$20K
- AbbVie$18K
- Pfizer$17K
- Bristol Myers Squibb$16K
- plus $66K from 31 others
What the payments were for
- Consulting fees$2,4582%
- Speaking & faculty fees$92,71473%
- Travel & lodging$3,6183%
- Food & beverage$26,71721%
- Education$7501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 86 | $113,128 |
| Mallinckrodt Hospital Products Inc. | 96 | $39,419 |
| Aurinia Pharma U.S., Inc. | 41 | $19,946 |
| AbbVie | 240 | $17,705 |
| Pfizer | 96 | $17,220 |
| Bristol Myers Squibb | 20 | $16,053 |
| Amgen(2 entities) | 240 | $14,485 |
| Eli Lilly | 2 | $13,841 |
| Genentech USA, Inc. | 37 | $10,258 |
| Mallinckrodt Enterprises LLC | 16 | $5,821 |
| Sanofi US Services Inc. | 15 | $5,492 |
| GSK | 56 | $4,516 |
| ANI Pharmaceuticals, Inc. | 27 | $3,023 |
| UCB, Inc. | 147 | $2,396 |
| Johnson & Johnson | 67 | $1,476 |
| AstraZeneca(2 entities) | 33 | $1,339 |
| E.r. Squibb & Sons, L.L.C. | 60 | $904 |
| Sanofi | 11 | $658 |
| Lilly USA, LLC | 33 | $587 |
| Radius Health, Inc. | 26 | $401 |
| Boehringer Ingelheim | 13 | $281 |
| Regeneron Healthcare Solutions, Inc. | 12 | $240 |
| Kyowa Kirin, Inc. | 2 | $140 |
| Janssen Scientific Affairs, LLC | 1 | $123 |
| Organon | 7 | $85 |
| Daiichi Sankyo Inc. | 4 | $71 |
| Medexus Pharma, Inc. | 5 | $59 |
| Actelion Pharmaceuticals US, Inc. | 3 | $48 |
| Sandoz | 2 | $36 |
| Bioventus LLC | 1 | $26 |
| EUSA Pharma (US) LLC | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Fresenius Kabi USA, LLC | 1 | $19 |
| Invivyd Inc | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Collegium Pharmaceutical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$289,896 in reported general payments places this provider in the 85th percentile of 90 rheumatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 44 | $2,797,003 |
| Humira(Cf) PenAdalimumab | 114 | $971,495 |
| Enbrel SureclickEtanercept | 117 | $863,315 |
| Cimzia (2 Pack)Certolizumab Pegol | 86 | $492,908 |
| RinvoqUpadacitinib | 65 | $411,728 |
| OrenciaAbatacept/Maltose | 79 | $363,358 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 57 | $265,074 |
| XeljanzTofacitinib Citrate | 34 | $240,634 |
| Taltz AutoinjectorIxekizumab | 35 | $235,266 |
| TremfyaGuselkumab | 17 | $227,403 |
| LupkynisVoclosporin | 15 | $220,725 |
| OtezlaApremilast | 40 | $199,989 |
| Simponi AriaGolimumab | 25 | $185,852 |
| RituxanRituximab | 19 | $182,715 |
| Cosentyx Unoready PenSecukinumab | 20 | $145,818 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $39,419 | $2,797,00344 claims |
| UCB, Inc.Cimzia (2 Pack) | $2,396 | $492,90886 claims |
| AbbVieRinvoq, Savella | $17,705 | $423,91478 claims |
| Johnson & JohnsonTremfya, Simponi Aria | $1,476 | $413,25542 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $904 | $363,35879 claims |
| PfizerXeljanz | $17,220 | $240,63434 claims |
| AmgenOtezla, Prolia | $14,485 | $228,62857 claims |
| Aurinia Pharma U.S., Inc.Lupkynis | $19,946 | $220,72515 claims |
| Radius Health, Inc.Tymlos | $401 | $99,35137 claims |
| GSKBenlysta | $4,516 | $85,93126 claims |
| SanofiKevzara | $658 | $61,31114 claims |
| Lilly USA, LLCOlumiant | $587 | $31,96812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 90 rheumatology providers in Alabama.
Other rheumatology in Northport
- Donna ManeiceNorthport$21K
- Brittany HillNorthport$20K
- Jeffrey CurtisBirmingham$17.6M
- Kenneth SaagBirmingham$8.2M
- Vishala ChindaloreAnniston$3.5M
- Anthony TurkiewiczMountain Brk$2.5M
- Harry SchroederBirmingham$938K
- Jose Rubio MosqueraBirmingham$823K
- David McLainBirmingham$588K
- William ShergyHuntsville$453K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.